Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.60 |
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.47 |
| ▸ | ABAT | P80404 | 1/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216212 | 0.95 | ALDH1A1 (0.58) | ALDH1A1AOX1FDPSHPGDTDP1 | |
| SCHEMBL13258617 | 0.94 | ALDH1A1 (0.57) | ALDH1A1AOX1FDPSHPGDTDP1 | |
| SCHEMBL14953129 | 0.94 | ALDH1A1 (0.57) | ALDH1A1AOX1FDPSHPGDTDP1 | |
| SCHEMBL3842399 | 0.94 | ALDH1A1 (0.57) | ALDH1A1AOX1FDPSHPGDTDP1 | |
| SCHEMBL1425341 | 0.92 | ALDH1A1 (0.62) | ALDH1A1AOX1FDPSHPGDTDP1 | |
| SCHEMBL15853568 | 0.88 | ALDH1A1 (0.61) | ALDH1A1AOX1FDPSHPGDTDP1 | |
| SCHEMBL16472557 | 0.88 | ALDH1A1 (0.61) | ALDH1A1AOX1FDPSHPGDTDP1 | |
| SCHEMBL2890759 | 0.87 | ALDH1A1 (0.73) | ALDH1A1AOX1FDPSHPGDTDP1 | |
| SCHEMBL21156471 | 0.86 | ALDH1A1 (0.55) | ALDH1A1AOX1FDPSHPGDTDP1 | |
| SCHEMBL15952644 | 0.86 | ALDH1A1 (0.63) | ALDH1A1AOX1FDPSHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362431-A1 | Carbidopa And L-Dopa Prodrugs And Methods Of Use | ABBVIE INC. | 2016-12-15 | — | — | US | disclosed |
| US-9446059-B2 | Carbidopa and L-dopa prodrugs and methods of use | ABBVIE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160106765-A1 | Carbidopa and L-Dopa Prodrugs and Methods of Use | ABBVIE INC. | 2016-04-21 | — | — | US | disclosed |
| US-20150352232-A1 | MR IMAGING DIAGNOSTIC AGENT FOR INTRACTABLE NEUROLOGICAL DISEASE | SHIGA UNIVERSITY OF MEDICAL SCIENCE (JP) | 2015-12-10 | — | — | US | disclosed |
| EP-2944626-A1 | MR IMAGING DIAGNOSTIC AGENT FOR INTRACTABLE NEUROLOGICAL DISEASE | Shiga University Of Medical Science (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-20150259373-A1 | NOVEL FLAVONOID COMPOUNDS AND USES THEREOF | ARMARON BIO PTY LTD (AU) | 2015-09-17 | — | — | US | disclosed |
| WO-2014109296-A1 | MR IMAGING DIAGNOSTIC AGENT FOR INTRACTABLE NEUROLOGICAL DISEASE | 国立大学法人滋賀医科大学 (JP) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014056038-A1 | NOVEL FLAVONOID COMPOUNDS AND USES THEREOF | NEUPROTECT PTY LTD (AU) | 2014-04-17 | — | — | WO | disclosed |
| EP-2557079-A1 | Synthesis of catechin and epicatechin conjugates | Nestec S.A. (CH) | 2013-02-13 | — | — | EP | disclosed |
| US-8318132-B2 | Imaging agents for detecting neurological dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7601742-B2 | 4-(3-Hydroxy-4-methoxyphenyl)-pyrrolidin-2-one and derivatives; reverse transcriptase inhibitors; AIDS | IRM LLC (BM) | 2009-10-13 | — | — | US | disclosed |
| US-7495016-B2 | Pyrrolidones with anti-HIV activity | IRM LLC (BM) | 2009-02-24 | — | — | US | disclosed |
| US-20080255136-A1 | PYRROLIDONES WITH ANTI-HIV ACTIVITY | IRM LLC (BM) | 2008-10-16 | — | — | US | disclosed |
| US-7112698-B2 | 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents | SPEAR THERAPEUTICS LIMITED (GB) | 2006-09-26 | — | — | US | disclosed |
| US-20040259957-A1 | 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents | SPEAR THERAPEUTICS LIMITED (GB) | 2004-12-23 | — | — | US | disclosed |
| EP-1432669-A1 | 4-(C2-6 ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003029176-A1 | 4-(C2-6ALKOXY)-SUBSTITUTED CHALCONES AS THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-04-10 | — | — | WO | disclosed |
| US-20020065309-A1 | Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists | AFFYMAX, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002011732-A1 | NOVEL BICYCLIC AND TRICYCLIC PYRROLIDINE DERIVATIVES AS GNRH ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255136-A1 | PYRROLIDONES WITH ANTI-HIV ACTIVITY | PREP, DHPS, PDCD11 | ALDH1A1 1894/4885AOX1 3298/4885FDPS 45/4885 |
| US-20150352232-A1 | MR IMAGING DIAGNOSTIC AGENT FOR INTRACTABLE NEUROLOGICAL DISEASE | TARDBP, FUS, SNCA | ALDH1A1 4676/4885AOX1 4748/4885FDPS 3020/4885 |
| US-20160362431-A1 | Carbidopa And L-Dopa Prodrugs And Methods Of Use | COMT, SNCA, PARK7 | ALDH1A1 694/4885AOX1 1355/4885FDPS 1760/4885 |
| US-20040259957-A1 | 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents | OXER1, ALK, BCL6 | ALDH1A1 390/4885AOX1 168/4885FDPS 2744/4885 |
| US-20150259373-A1 | NOVEL FLAVONOID COMPOUNDS AND USES THEREOF | BAX, CASP3, BAD | ALDH1A1 410/4885AOX1 175/4885FDPS 692/4885 |
| US-20160106765-A1 | Carbidopa and L-Dopa Prodrugs and Methods of Use | COMT, SNCA, PARK7 | ALDH1A1 694/4885AOX1 1355/4885FDPS 1760/4885 |
| US-20020065309-A1 | Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists | GNRHR, FSHR, LHCGR | ALDH1A1 4778/4885AOX1 4649/4885FDPS 3287/4885 |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | FABP7, SLC18A3, TSPO | ALDH1A1 3189/4885AOX1 1358/4885FDPS 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.